CORRESP 1 filename1.htm

 

Ladenburg Thalmann & Co. Inc.

640 Fifth Avenue, 4th Floor

New York, New York 10019

 

 

 

December 15, 2023

 

 

VIA FACSIMILE AND EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, DC 20549

 

  Re:   Biodexa Pharmaceuticals Plc
      Registration Statement on Form F-1 (Registration No. 333-274895)
      Concurrence in Acceleration Request

 

Ladies and Gentlemen:

 

Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Biodexa Pharmaceuticals Plc that the effective date of the above-referenced registration statement be accelerated to 5:30 p.m. (Eastern Time), or as soon as practicable thereafter, on December 18, 2023, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.

 

    Very truly yours,
       
    LADENBURG THALMANN & CO. INC.
       
       
       
    By: /s/ Nicholas Stergis  
      Name: Nicholas Stergis
      Title: Managing Director